TRMD - Marinus Pharmaceuticals Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session | Benzinga
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
Shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) fell sharply in today’s pre-market trading after the company issued an update on the Phase 3 RAISE Trial and reported preliminary first quarter 2024 financial results.
Marinus Pharma reported Prelim ZTALMY (Ganaxolone) net product revenue of $7.4 million to $7.6 million for the first quarter.
Marinus Pharmaceuticals shares dipped 74.2% to $1.94in pre-market trading.
Here are ...